Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEPEZZA SubQ PK Study in Healthy Adults
NCT06563856Phase 1Completed
- Sponsor
- Amgen
- Start
- Sep 2020
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of teprotumumab in thyroid eye disease (TED) (4 arms), sponsored by Amgen. Primary endpoints: Area Under the Serum Concentration-time Curve From Time 0 Extrapolated to Infinity, Area Under the Serum Concentration-time Curve From Time 0 to the Last Quantifiable Concentration and 2 more. Started Sep 2020; status: completed.
02
Drugs
teprotumumab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06563856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06563856.